The Impact of Immune Checkpoint Inhibitors on Fertility Preservation and Pregnancy Outcomes
Authors:
- Agata ProkopiukAPAgata Prokopiuk
- Adrianna TabeauATAdrianna Tabeau
- Agnieszka PawlikAPAgnieszka Pawlik
- Patryk DudekPDPatryk Dudek
- Klaudia ŁuczakKŁKlaudia Łuczak
- Wiktoria UlickaWUWiktoria Ulicka
- Justyna PiętaJPJustyna Pięta
- Hanna SitarekHSHanna Sitarek
- Joanna PrusJPJoanna Prus
- Marcel ChudzikowskiMCMarcel Chudzikowski
Open Access
- 2 May 2025
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 81, 60024
Abstract
Immune checkpoint inhibitors have revolutionized cancer treatment by enhancing anti-tumor immune responses. However, their impact on fertility is an emerging concern, particularly among young patients, including children. This review aims to assess the effects of immune checkpoint inhibitors on reproductive health and fertility preservation strategies. Immune checkpoint inhibitors may cause endocrine-related adverse effects, such as hypophysitis, thyroid dysfunction, and adrenal insufficiency, which can disrupt gonadal function. In women, these therapies may reduce ovarian reserve, impair ovulation, and cause menstrual irregularities. In men, they may contribute to testosterone deficiency and reduced sperm production. Given that immune checkpoint inhibitors are used even in pediatric oncology, early fertility counseling and preservation strategies, such as oocyte and sperm cryopreservation, should be discussed before treatment. Additionally, recent evidence suggests that physical activity may have a protective effect on reproductive health in patients receiving these therapies by regulating hormonal balance and reducing inflammation. Immune checkpoint inhibitor therapy may contribute to pregnancy-related disorders, with reported adverse effects including miscarriage and preterm birth, however some studies document successful pregnancies in women exposed to this treatment. As immune checkpoint inhibitors continue to be widely used, further research is needed to clarify their long-term effects on reproductive health and optimize fertility preservation strategies for affected patients.Keywords
This publication has 30 references indexed in Scilit:
- Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumorsEuropean Journal of Cancer, 2024
- LAG-3 as the third checkpoint inhibitorNature Immunology, 2023
- Immune mechanisms of toxicity from checkpoint inhibitorsTrends in Cancer, 2023
- Investigation of the female infertility risk associated with anti-cancer therapyClinical and Translational Oncology, 2023
- Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in miceNature Cancer, 2022
- Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic reviewESMO Open, 2021
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialThe Lancet Oncology, 2020
- A decade of immune-checkpoint inhibitors in cancer therapyNature Communications, 2020
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011